Advertisements

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab.....»»

Category: press-releasesSource: businesswireindiaJan 11th, 2017

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Pegfilgrastim for Review

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Pegfilgrastim for Review.....»»

Category: press-releasesSource: businesswireindiaFeb 16th, 2017

USFDA issues CRL for proposed biosimilar Pegfilgrastim: Biocon

USFDA issues CRL for proposed biosimilar Pegfilgrastim: Biocon.....»»

Category: topSource: moneycontrolOct 10th, 2017

Biocon soars over 7% as USFDA issues CRL for proposed biosimilar

Biocon soars over 7% as USFDA issues CRL for proposed biosimilar.....»»

Category: marketsSource: thehindubusinesslineOct 10th, 2017

Biocon jumps over 3% as USFDA issues CRL for proposed biosimilar

Biocon jumps over 3% as USFDA issues CRL for proposed biosimilar.....»»

Category: marketsSource: thehindubusinesslineOct 10th, 2017

EMA accepts Biocon, Mylan biosimilar for review

EMA accepts Biocon, Mylan biosimilar for review.....»»

Category: topSource: the-hinduAug 25th, 2016

Biocon gains 2% as Mylan resubmits marketing authorization applications to EMA

Biocon gains 2% as Mylan resubmits marketing authorization applications to EMA.....»»

Category: topSource: moneycontrolNov 6th, 2017

Biocon in focus as breast cancer biosimilar gets US FDA advisory panel’s endorsement

Biocon in focus as breast cancer biosimilar gets US FDA advisory panel’s endorsement.....»»

Category: topSource: moneycontrolJul 13th, 2017

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Mylan-Biocon seek USFDA nod for biosimilar version of cancer drug

Mylan-Biocon seek USFDA nod for biosimilar version of cancer drug.....»»

Category: featuresSource: livemintNov 9th, 2016

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab.....»»

Category: press-releasesSource: businesswireindiaNov 8th, 2016

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab.....»»

Category: press-releasesSource: businesswireindiaNov 8th, 2016

Trastuzumab marketing approval may come in 12-18 months: Biocon

Trastuzumab marketing approval may come in 12-18 months: Biocon.....»»

Category: topSource: moneycontrolAug 26th, 2016

EMA accepts Mylan, Biocon Trastuzumab biosimilar for review

EMA accepts Mylan, Biocon Trastuzumab biosimilar for review.....»»

Category: topSource: moneycontrolAug 25th, 2016

Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency

Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency.....»»

Category: press-releasesSource: businesswireindiaAug 25th, 2016

Mylan, Biocon report efficacy of cancer drug

Mylan, Biocon report efficacy of cancer drug.....»»

Category: topSource: the-hinduJun 5th, 2016

Mylan, Biocon confirm efficacy of trastuzumab biosimilar

Mylan, Biocon confirm efficacy of trastuzumab biosimilar.....»»

Category: topSource: moneycontrolJun 4th, 2016

Closing bell: Sensex, Nifty close flat; IT, metals, PSU banks stocks gain

Closing bell: Sensex, Nifty close flat; IT, metals, PSU banks stocks gain.....»»

Category: marketsSource: moneycontrolDec 4th, 2017